Elevance Health Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Gail Boudreaux
Algemeen directeur
US$21.9m
Totale compensatie
| Percentage CEO-salaris | 7.3% |
| Dienstverband CEO | 7yrs |
| Eigendom CEO | 0.05% |
| Management gemiddelde ambtstermijn | 6.8yrs |
| Gemiddelde ambtstermijn bestuur | 11.3yrs |
Recente managementupdates
Recent updates
We Think Elevance Health's (NYSE:ELV) Profit Is Only A Baseline For What They Can Achieve
Oct 29
Elevance Health: A Bad Q3 Was Almost Inevitable Given Industry Headwinds
Oct 17Elevance: Our Top Value Pick Trading At 12.5x Earnings And Growing At 12.5%
Oct 10Is Now An Opportune Moment To Examine Elevance Health, Inc. (NYSE:ELV)?
Oct 08Investors Continue Waiting On Sidelines For Elevance Health, Inc. (NYSE:ELV)
Sep 11Elevance Health: Strong Earnings Growth Supports Strong Dividend Growth
Sep 06There's Been No Shortage Of Growth Recently For Elevance Health's (NYSE:ELV) Returns On Capital
Aug 29Here's Why We Think Elevance Health (NYSE:ELV) Is Well Worth Watching
Aug 02Elevance Health: Healthcare Services Segment Is Gaining Traction
Jul 31Elevance Health: Buy A Dividend Growth Machine
Jul 18Elevance Health: Favorable Trends Are Emerging (Rating Upgrade)
Jun 28Is Now An Opportune Moment To Examine Elevance Health, Inc. (NYSE:ELV)?
Jun 11Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
May 27We Think Shareholders Will Probably Be Generous With Elevance Health, Inc.'s (NYSE:ELV) CEO Compensation
May 09Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63
Apr 25Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23Is Elevance Health (NYSE:ELV) Using Too Much Debt?
Apr 16Elevance Health: Not Doing Enough In 2024 To Justify Premium Price
Apr 11Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors
Apr 01Elevance: A Healthy Dose Of Dividend Growth
Mar 21Elevance Heath: Financial Growth And Technical Strength Indicate A Buy
Mar 07Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63
Feb 19Elevance Health: Time To Buy This Incredible Dividend Growth Stock
Jan 26Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement
Jan 19Is Elevance Health (NYSE:ELV) A Risky Investment?
Jan 02Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story
Dec 18A Look At Elevance's Margin Dynamics
Nov 23Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?
Nov 16Elevance Health: A High Conviction Defensive Blue Chip Buy
Oct 19These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely
Oct 04Elevance: Pave The Way For The Next UnitedHealth
Sep 21Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Sep 18Here's The Price I Would Buy Elevance Health Stock
Sep 13If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity
Aug 18Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
Aug 04Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental
Jul 24Elevance Health: Beaten Down Share Price Offers Solid Potential
Jul 10Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly
Jul 05Elevance Health: A Critical Update (Rating Downgrade)
Jun 05Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
Jun 04Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
May 05We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt
Apr 04Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$6b |
| Jun 30 2024 | n/a | n/a | US$7b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$22m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$17m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$5b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$15m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$4b |
| Dec 31 2018 | US$14m | US$1m | US$4b |
| Sep 30 2018 | n/a | n/a | US$5b |
| Jun 30 2018 | n/a | n/a | US$4b |
| Mar 31 2018 | n/a | n/a | US$4b |
| Dec 31 2017 | US$3m | US$162k | US$4b |
Compensatie versus markt: De totale vergoeding ($USD 21.89M ) Gail } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).
Compensatie versus inkomsten: De vergoeding van Gail is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Gail Boudreaux (63 yo)
7yrs
Tenure
US$21,889,039
Compensatie
Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7yrs | US$21.89m | 0.047% $ 47.2m | |
| Executive VP & CFO | less than a year | US$12.36m | 0.0017% $ 1.7m | |
| Executive VP and Chief Legal & Administrative Officer | 4yrs | US$8.11m | 0.0044% $ 4.4m | |
| Executive VP and President of Carelon & CarelonRx | 10.4yrs | US$6.98m | 0.0071% $ 7.0m | |
| Executive VP & President of Government Health Benefits | 6.4yrs | US$6.48m | 0.0098% $ 9.7m | |
| SVP, Treasurer & Chief Investment Officer | 6.6yrs | geen gegevens | geen gegevens | |
| Senior VP | 9yrs | geen gegevens | 0.00057% $ 567.6k | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Public Affairs | 11yrs | geen gegevens | geen gegevens | |
| Chief Strategy Officer & Interim Chief Marketing Officer | less than a year | geen gegevens | geen gegevens | |
| Executive VP & President of Commercial Health Benefits | no data | geen gegevens | 0.0022% $ 2.2m | |
| President of Dental Business | 8yrs | geen gegevens | geen gegevens |
6.8yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ELV is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7yrs | US$21.89m | 0.047% $ 47.2m | |
| Independent Director | 20yrs | US$386.76k | 0.0024% $ 2.4m | |
| Independent Chair of the Board | 11.1yrs | US$597.83k | geen gegevens | |
| Independent Director | 11.3yrs | US$362.53k | geen gegevens | |
| Independent Director | 6.8yrs | US$371.42k | geen gegevens | |
| Independent Director | 10.5yrs | US$371.42k | geen gegevens | |
| Independent Director | 5.1yrs | US$347.28k | 0.0013% $ 1.3m | |
| Independent Director | 13.3yrs | US$360.34k | 0.0031% $ 3.1m | |
| Member of Advisory Board | 11.3yrs | geen gegevens | geen gegevens | |
| Member of Advisory Board | 11.3yrs | geen gegevens | geen gegevens | |
| Member of Advisory Board | 11.3yrs | geen gegevens | geen gegevens | |
| Member of Advisory Board | 11.3yrs | geen gegevens | geen gegevens |
11.3yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ELV zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.3 jaar).